866-997-4948(US-Canada Toll Free)

Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Published By :

Transparency Market Research

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 185 Pages

Global Monoclonal Antibody Therapeutics Market: Overview

Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous, and others. Monoclonal antibody are target specific in action by not affect the other cells of the body thus restores the immune system.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on application, source, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the monoclonal antibody therapeutics market in the current and future scenario.

Global Monoclonal Antibody Therapeutics Market: Segmentation

This report analyzes the current and future prospects of the monoclonal antibody therapeutics market based on type of application, source, end user and geography. By application monoclonal antibodies are segmented according to the therapeutic area such as cancer, autoimmune diseases, infection, hematological diseases, ophthalmological diseases and others which include monoclonal antibodies used in treating cardiovascular, respiratory, and orthopedic disorders as well as monoclonal antibodies used in the prevention of transplant rejection.

By source monoclonal antibodies are segmented into human, humanized, chimeric, and others, which include peptide body and murine antibodies. The human monoclonal antibody segment is expected to be highest contributing segment in the monoclonal antibody therapeutic market during the forecast period. Various factors such as patent expiry of block buster drugs, robust pipeline of monoclonal antibodies indicated in the treating various types of cancer and other disorders such as hematological, cardiovascular and orthopedic and upcoming biosimilars, define the market growth over the forecast period.

Global Monoclonal Antibody Therapeutics Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major monoclonal antibody therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases.

The report provides estimated market size in terms of US$ Mn for each by application, source, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, annual revenue generated by products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies.

Global Monoclonal Antibody Therapeutics Market: Regional Outlook

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the monoclonal antibody therapeutics market.

Key Players Mentioned in this Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the monoclonal antibody therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline Plc., Merck & Co., Inc., Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol – Myers Squibb Company and  Biogen Inc.   .

The monoclonal antibody therapeutics market has been segmented as follows:

Monoclonal Antibody Therapeutics Market, by Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others

Monoclonal Antibody Therapeutics Market, by Source

  • Human
  • Humanized
  • Chimeric
  • Others

Monoclonal Antibody Therapeutics Market, by End Users

  • Hospitals
  • Private Clinics
  • Research Institute

Monoclonal Antibody Therapeutics Market, by Geography

  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Europe
  • U.K.
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • India
  • Japan
  • China
  • Australia
  • New Zealand
  • Rest of Asia Pacific
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • A.E.
  • Rest of MEA

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Monoclonal Antibody Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Application Definition
4.1.2. Industry Evolution / Developments
4.2.Overview
4.3. Key Market Indicators
4.3.1. Region/Country Specific
4.3.2. Product/Application/End Users Specific
4.3.3. Target Market Specific – Global Scenario
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Monoclonal Antibody Therapeutics MarketAnalysis and Forecasts, 2014–2024
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Monoclonal Antibody Therapeutics Market- Global Supply Demand Scenario
4.7. Porter’s Five Force Analysis
4.8. Value Chain Analysis
4.9. Market Outlook

5. Global Monoclonal Antibody Therapeutics MarketAnalysis and Forecasts, By Application
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Key Trends
5.4. Market ValueForecast By Application , 2014–2024
5.4.1. Cancer
5.4.2. Autoimmune diseases
5.4.3. Infection
5.4.4. Hematological diseases
5.4.5. Ophthalmological diseases
5.4.6. Others
5.5. Market Attractiveness By Application

6. Global Monoclonal Antibody Therapeutics MarketAnalysis and Forecasts, By Source
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Market ValueForecast By Source , 2014–2024
6.4.1. Human
6.4.2. Humanized
6.4.3. Chimeric
6.4.4. Others
6.5. Market Attractiveness By Source

7. Global Monoclonal Antibody Therapeutics MarketAnalysis and Forecasts, By End Users
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Key Trends
7.4. Market ValueForecast By End Users , 2014–2024
7.4.1. Hospital
7.4.2. Private Clinic
7.4.3. Research Institutes
7.5. Market Attractiveness By End Users

8. Global Monoclonal Antibody Therapeutics MarketAnalysis and Forecasts, By Region
8.1. Key Findings
8.2. Policies and Regulations
8.3. Market ValueForecast By Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Market Attractiveness By Country/Region

9. North America Monoclonal Antibody Therapeutics MarketAnalysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market ValueForecast By Application , 2014–2024
9.2.1. Cancer
9.2.2. Autoimmune diseases
9.2.3. Infection
9.2.4. Hematological diseases
9.2.5. Ophthalmological diseases
9.2.6. Others
9.3. Market ValueForecast By Source , 2014–2024
9.3.1. Human
9.3.2. Humanized
9.3.3. Chimeric
9.3.4. Others
9.4. Market ValueForecast By End Users , 2014–2024
9.4.1. Hospital
9.4.2. Private Clinic
9.4.3. Research Institutes
9.5. Market ValueForecast By Country , 2014–2024
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Application
9.6.2. By Source
9.6.3. By End Users
9.6.4. By Country

10. Europe Monoclonal Antibody Therapeutics MarketAnalysis and Forecast
10.1.Introduction
10.1.1. Key Findings
10.1.4. Key Trends
10.2.Market ValueForecast By Application , 2014–2024
10.2.1. Cancer
10.2.2. Autoimmune diseases
10.2.3. Infection
10.2.4. Hematological diseases
10.2.5. Ophthalmological diseases
10.2.6. Others
10.3.Market ValueForecast By Source , 2014–2024
10.3.1. Human
10.3.2. Humanized
10.3.3. Chimeric
10.3.4. Others
10.4.Market ValueForecast By End Users , 2014–2024
10.4.1. Hospital
10.4.2. Private Clinic
10.4.3. Research Institutes
10.5.Market ValueForecast By Country , 2014–2024
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6.Market Attractiveness Analysis
10.6.1. By Application
10.6.2. By Source
10.6.3. By End Users
10.6.4. By Country

11. Asia Pacific Monoclonal Antibody Therapeutics MarketAnalysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.1.4. Key Trends
11.2.Market ValueForecast By Application , 2014–2024
11.2.1. Cancer
11.2.2. Autoimmune diseases
11.2.3. Infection
11.2.4. Hematological diseases
11.2.5. Ophthalmological diseases
11.2.6. Others
11.3.Market ValueForecast By Source , 2014–2024
11.3.1. Human
11.3.2. Humanized
11.3.3. Chimeric
11.3.4. Others
11.4.Market ValueForecast By End Users , 2014–2024
11.4.1. Hospital
11.4.2. Private Clinic
11.4.3. Research Institutes
11.5.Market ValueForecast By Country , 2014–2024
11.5.1. Japan
11.5.2. China
11.5.3. Australia
11.5.4. New Zealand
11.5.5. India
11.5.6. Rest of Asia Pacific
11.6.Market Attractiveness Analysis
11.6.1. By Application
11.6.2. By Source
11.6.3. By End Users
11.6.4. By Country

12. Latin AmericaMonoclonal Antibody Therapeutics MarketAnalysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.1.4. Key Trends
12.2.Market ValueForecast By Application , 2014–2024
12.2.1. Cancer
12.2.2. Autoimmune diseases
12.2.3. Infection
12.2.4. Hematological diseases
12.2.5. Ophthalmological diseases
12.2.6. Others
12.3.Market ValueForecast By Source , 2014–2024
12.3.1. Human
12.3.2. Humanized
12.3.3. Chimeric
12.3.4. Others
12.4.Market ValueForecast By End Users , 2014–2024
12.4.1. Hospital
12.4.2. Private Clinic
12.4.3. Research Institutes
12.5.Market ValueForecast By Country , 2014–2024
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6.Market Attractiveness Analysis
12.6.1. By Application
12.6.2. By Source
12.6.3. By End Users
12.6.4. By Country

13. Middle East & Africa Monoclonal Antibody Therapeutics MarketAnalysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.1.4. Key Trends
13.2.Market ValueForecast By Application , 2014–2024
13.2.1. Cancer
13.2.2. Autoimmune diseases
13.2.3. Infection
13.2.4. Hematological diseases
13.2.5. Ophthalmological diseases
13.2.6. Others
13.3.Market ValueForecast By Source , 2014–2024
13.3.1. Human
13.3.2. Humanized
13.3.3. Chimeric
13.3.4. Others
13.4.Market ValueForecast By End Users , 2014–2024
13.4.1. Hospital
13.4.2. Private Clinic
13.4.3. Research Institutes
13.5.Market ValueForecast By Country , 2014–2024
13.5.1. South Africa
13.5.2. UAE
13.5.3. Saudi Arabia
13.5.4. Rest of Middle East and Africa
13.6.Market Attractiveness Analysis
13.6.1. By Application
13.6.2. By Source
13.6.3. By End Users
13.6.4. By Country

14. Competition Landscape
14.1.Market Player – Competition Matrix (By Tier and Size of companies)
14.2.Market Share Analysis By Company (2015)
14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. Bayer AG
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. F. Hoffmann-La Roche Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Pfizer, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sanofi
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. GlaxoSmithKline plc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Merck & Co., Inc.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Novartis AG
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. AbbVie Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Amgen Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
14.3.10. Johnson & Johnson
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Financial Overview
14.3.10.3. Product Portfolio
14.3.10.4. SWOT Analysis
14.3.10.5. Strategic Overview
14.3.11. Bristol-Myers Squibb Company
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Financial Overview
14.3.11.3. Product Portfolio
14.3.11.4. SWOT Analysis
14.3.11.5. Strategic Overview
14.3.12. Biogen Inc.
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Financial Overview
14.3.12.3. Product Portfolio
14.3.12.4. SWOT Analysis
14.3.12.5. Strategic Overview

List of Table

Table 01: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 02: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 03: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by End Users, 2014–2024
Table 04: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 06: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 07: North America Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 08: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 09: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 10: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 11: Europe Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 12: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 14: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 15: Asia Pacific Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 16: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 18: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 19: Latin America Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 20: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 21: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 22: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 23: MEA Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 24: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Chart

Figure  1: Market Value Share By Application (2016) Revenue (US$ Mn)
Figure  2: Market Value Share By Source(2016) Revenue (US$ Mn)
Figure  3: Market Value Share By Application & Source (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users  (2016) Revenue (US$ Mn)
Figure  4: Market Value Share By Region (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users & Region (2016) Revenue (US$ Mn)
Figure  5: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  6: Global Cancer  Market Revenue (US$ Mn), 2014–2024
Figure  7: Global Autoimmune diseases Market Revenue (US$ Mn), 2014–2024
Figure  8: Global Infection Market Revenue (US$ Mn), 2014–2024
Figure  9: Global Hematological diseases  Market Revenue (US$ Mn), 2014–2024
Figure  10: Global Ophthalmic diseases Market Revenue (US$ Mn), 2014–2024
Figure  11: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  12: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Application, 2015
Figure  13: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  14: Global Human Market Revenue (US$ Mn), 2014–2024
Figure  15: Global Humanized Market Revenue (US$ Mn), 2014–2024
Figure  16: Global Chimeric Market Revenue (US$ Mn), 2014–2024
Figure  17: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  18: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Source, 2015
Figure  19: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  20: Global Hospital Market Revenue (US$ Mn), 2014–2024
Figure  21: Global Private Clinics Market Revenue (US$ Mn), 2014–2024
Figure  22: Global Research Institutes  Market Revenue (US$ Mn), 2014–2024
Figure  23: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By End Users, 2015
Figure  24: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
Figure  25: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Region, 2015
Figure  26: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  27: North America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  28: North America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  29: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  30: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  31: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  32: North America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  33: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  34: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  35: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, By End users, 2015
Figure  36 : Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  37: Europe Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  38: Europe Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  39: Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  40 : Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  41: Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  42: Europe Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  43: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  44: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  45: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  46: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  47: Asia Pacific Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  48: Asia Pacific Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  49: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  50: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  51: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  52: Asia Pacific Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  53: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  54: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  55: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  56: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  57: Latin America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  58: Latin America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  59: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  60: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  61: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  62: Latin America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  63: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  64: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  65: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  66: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  67: MEA Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  68: MEA Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  69: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  70: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  71: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  72: MEA Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  73: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  74: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  75: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  76: Global Monoclonal Antibody Therapeutics Market Share Analysis, by Company (2015)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *